Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • EAACI-WAO Congress on Allergy and Asthma

Faster and better symptom control in allergic rhinitis

    • Congress Reports
    • Dermatology and venereology
    • ORL
    • RX
  • 2 minute read

Asthma and allergies are becoming increasingly important. Their treatment is often unsatisfactory, for example, many patients with allergic rhinitis complain of inadequate control of their nasal and ocular symptoms. A reformulated nasal spray containing azelastine and fluticasone may provide relief in the future.

The EAACI (European Academy of Allergy and Clinical Immunology) and WAO (World Allergy Organization), in one of their official communications to the congress, speak of the fact that more and more people worldwide are suffering from allergies or asthma. There is still a need for improvement in the treatment of these diseases. “For example, in an American survey, nearly half of patients with allergic rhinitis found that their symptoms were not optimally controlled,” explained Eli Meltzer, MD, USA [1]. “Symptoms around the nose and eyes in particular are poorly controlled by current monotherapy or combination therapies,” Dr. Meltzer emphasized. The newly formulated nasal spray with the active ingredients azelastine and fluticasone presented at the congress could possibly fulfill his wish for more effective treatment options.

 

Better symptom control with new nasal spray

In a randomized, double-blind, placebo-controlled trial, patients with moderate to severe seasonal allergic rhinitis were treated with either MP29-02, a nasal spray containing fluticasone propionate, a spray containing azelastine, or placebo for 14 days after a seven-day placebo period [2]. At baseline, patients had an rTNSS (“Reflective Total Nasal Symptom Score”) of 18-19 (max = 24) and an rTOSS (“Reflective Total Ocular Symptom Score”) of 11-12 (max = 18). As was shown, all symptoms making up the rTNSS score (rhinorrhea, nasal congestion, itching, sneezing) improved significantly more under MP29-02 than when using a currently available product with the respective single component. This could also be demonstrated in a comparable manner for the rTOSS. “Relevant improvement in nasal symptoms was achieved days earlier with MP29-02 than with azelastine or fluticasone alone,” Dr. Meltzer concluded [3].

Source: EAACI-WAO Congress, June 22-26, 2013, Milan.

Literature:

  1. Meltzer EO, et al: Allergic rhinitis substantially impacts patient quality of life: findings from the Nasal Allergy Survey Assessing Limitations. J Fam Pract 2012; 61(2): 5-10.
  2. Hampel FC, et al: Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 2010; 105: 168-73.
  3. Bachert C, et al: MP29-02 and Time to Response in the Treatment of Seasonal Allergic Rhinitis Compared to Marketed Antihistamine and Corticosteroid Nasal Sprays. European Academy of Allergy and Clinical Immunology (EAACI) Congress 2011, Abstract 285.
Autoren
  • Dr. Therese Schwender
Publikation
  • DERMATOLOGIE PRAXIS
Related Topics
  • Allergic rhinitis
  • Allergy
  • Asthma
  • Azelastine
  • EAACI-WAO
  • Fluticasone
  • Mono- or combination therapies
Previous Article
  • Food allergies - part 1

The hundred-year history of food allergies

  • Allergology and clinical immunology
  • Dermatology and venereology
  • Education
  • Nutrition
  • Prevention and health care
  • RX
View Post
Next Article
  • Rosacea

Addressing known factors with therapy

  • Congress Reports
  • Dermatology and venereology
  • RX
View Post
You May Also Like
View Post
  • 6 min
  • Past, present and future

Biomarkers in schizophrenia

    • Education
    • Genetics
    • Neurology
    • Psychiatry and psychotherapy
    • RX
    • Studies
View Post
  • 7 min
  • From genome profiles to targeted therapies

Advances in breast cancer therapy in the age of molecular diagnostics

    • Education
    • Genetics
    • Gynecology
    • Oncology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 6 min
  • Current overview of evidence, mechanisms and clinical implications

Apolipoprotein E and neuropsychiatric symptoms in neurocognitive disorders

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 7 min
  • Rare pulmonary syndromes

Yellow nail and Swyer-James syndrome

    • CME continuing education
    • Dermatology and venereology
    • General Internal Medicine
    • Infectiology
    • Pneumology
    • RX
View Post
  • 12 min
  • Parkinson's disease

Individual therapy management for an optimized outcome – an update

    • CME continuing education
    • Neurology
    • RX
    • Studies
    • Training with partner
View Post
  • 6 min
  • Latent autoimmune diabetes in adults (LADA)

Looks like type 2, but is type 1

    • Cases
    • Education
    • Endocrinology and Diabetology
    • RX
    • Studies
View Post
  • 6 min
  • Treatment of vitiligo

Focus on patient perspective and disease activity

    • Congress Reports
    • Dermatology and venereology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 5 min
  • Vaccine-preventable respiratory diseases

RSV and pneumococci: recommendations for risk groups

    • Congress Reports
    • General Internal Medicine
    • Infectiology
    • Pediatrics
    • Pneumology
    • Prevention and health care
    • RX
    • Studies
Top Partner Content
  • Herpes zoster

    Zum Thema
Top CME content
  • 1
    Yellow nail and Swyer-James syndrome
  • 2
    Individual therapy management for an optimized outcome – an update
  • 3
    Doing sport without fear or risk
  • 4
    UV protection and skin cancer screening – Update 2025
  • 5
    Rare malignancy from a dermatological perspective

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.